GSK has announced the availability of its much-anticipated cancer therapies, Jemperli (dostarlimab) and Zejula (niraparib), in India, reinforcing its commitment to offering specialised treatments for women’s cancers. Gynaecological cancers, including endometrial and ovarian cancers, are among the most common in Indian women and their incidence continues to rise. By 2045, endometrial cancer cases are projected to increase by 78%, while ovarian cancer cases are expected to rise by 69%, highlighting the urgent need for effective treatment options.
Endometrial cancer, which develops in the inner lining of the uterus, is often diagnosed at an advanced stage in nearly a quarter of patients in India. Chemotherapy has traditionally been the standard treatment, but it is frequently associated with toxicity and limited long-term outcomes. Jemperli, the first and only approved PD-1 immunotherapy in India for second-line treatment of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer, works by blocking the PD-1 pathway. This enables the immune system to better detect and attack cancer cells. Evidence from the GARNET trial demonstrated that Jemperli achieved an objective response rate of 45.5%, with maintained response probabilities of 93.3% at 12 months and 83.7% at 24 months, showing durable clinical benefits for patients who previously had limited options.
Ovarian cancer, which begins in the ovaries, remains a significant health challenge in India. Zejula is the only PARP inhibitor approved as a first-line monotherapy maintenance treatment for all biomarker types in advanced ovarian cancer. With a convenient once-daily oral dose, Zejula provides an accessible treatment option for patients. Updated analyses from the phase-3 PRIMA trial showed that Zejula first-line maintenance therapy offers long-term remission for women with newly diagnosed advanced ovarian cancer, regardless of biomarker status, helping reduce the risk of disease progression.
To support patients in accessing these therapies, GSK has introduced the Phoenix Patient Support Program, aimed at empowering patients and improving access to innovative cancer care. The launch of Jemperli and Zejula in India marks a significant step forward in treating endometrial and ovarian cancers, offering hope for better outcomes through advanced, evidence-backed therapies.
